Game Changing Signals from Global Regulatory Agencies Accompany IVRO Sales and Profit Gains

InVitro International (OTCQB: IVRO) reported FY 2025 sales of $878,937, a rise of 8.3% versus FY 2024, and net income of $121,980, up 14.3% year‑over‑year.

Rhea-AI Summary

InVitro International (OTCQB: IVRO) reported FY 2025 sales of $878,937, a rise of 8.3% versus FY 2024, and net income of $121,980, up 14.3% year‑over‑year.

Management highlighted global regulatory developments saying some Regulatory Agencies have already, or will soon, cease funding animal testing and that certain agencies indicated OECD‑validated non‑animal test results could be accepted immediately. The company positions its in vitro test methods for large end markets including cosmetics, chemical companies, and adhesives manufacturers.

Positive

• Net income +14.3% YoY in FY 2025
• FY 2025 sales $878,937 (up 8.3% YoY)
• Company offers OECD‑validated non‑animal test methods

Negative

• FY 2025 sales remain under $1,000,000
• Sales growth +8.3% YoY (single‑digit increase)

Argus Dec 9 session

+1.08% close to close Open Argus

Details

News Market Reaction – IVRO

On Dec 9, the day this news came out, IVRO closed 1.08% above the previous close.

Data tracked by StockTitan Argus for the Dec 9 session.

Market Context

This announcement highlights FY 2025 sales of $878,937, up 8.3%, and net income of $121,980, up 14.3...

Analysis

This announcement highlights FY 2025 sales of $878,937, up 8.3%, and net income of $121,980, up 14.3%, alongside signals from global Regulatory Agencies reducing funding for animal testing and accepting OECD‑validated non‑animal methods. Earlier in FY ’25, IVRO also reported strong Q3 and year‑to‑date growth. Investors may monitor how quickly these regulatory shifts translate into demand from cosmetics, chemical, and adhesives customers, as well as changes in trading liquidity versus the 32,967 share average.

Key Figures

FY 2025 Sales: $878,937 Sales Growth: 8.3% FY 2025 Net Income: $121,980 +1 more

FY 2025 Sales

$878,937

Full year 2025

Sales Growth

8.3%

FY 2025 vs FY 2024

FY 2025 Net Income

$121,980

Full year 2025

Net Income Growth

14.3%

FY 2025 vs FY 2024

Historical Context

2 past events · Latest: Dec 09

2 events

1. Dec 09

   Full-year results

   24h Move

   +1.1%

   FY 2025 sales and net income growth plus supportive regulatory signals.

2. Aug 05

   Quarterly results

   24h Move

   +37.3%

   Strong Q3 and YTD growth with growing support for in vitro testing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

otcqb, regulatory agencies, oecd, in vitro testing

4 terms

otcqb financial

"Today, InVitro International (OTCQB: IVRO) reported FY '25 sales..."

OTCQB is a tier of the over‑the‑counter (OTC) market where smaller or developing companies list their shares for trading without being on a major stock exchange. Think of it like a well‑kept side street market: companies must meet basic reporting and transparency checks so investors get more information than the lowest OTC tier, but trading is usually less liquid and riskier than on big exchanges. Investors care because OTCQB listings can offer early access to growth stories but come with higher price swings and greater chance of limited resale options.

View in glossary

regulatory agencies regulatory

"Regulatory Agencies around the world announced they have already..."

Regulatory agencies are government bodies that set and enforce rules for industries—like referees or traffic lights for markets and products—to protect public safety, fair competition, and accurate information. For investors, their decisions on approvals, inspections, fines or rule changes can change a company’s ability to sell products, add costs, delay projects or affect reputation, making them a key driver of risk and future profits.

oecd regulatory

"some RA's state OECD validated NON-animal test results could be accepted..."

A group of mostly developed countries that collects economic data, writes policy guidelines, and publishes comparative reports on growth, taxes, trade and regulation; think of it as a referee and scoreboard for international economic rules and performance. Investors watch its studies and recommendations because they help shape tax policies, cross-border trade and regulatory standards, which influence company profits, market access and the risks and opportunities in different countries.

in vitro testing medical

"industry movement from animal databased safety testing to in vitro testing..."

In vitro testing is laboratory testing of cells, tissues, or biological molecules done outside a living organism, typically in dishes or tubes. For investors, it matters because these experiments are an early, controlled way to show whether a drug, diagnostic, or biotech process has the expected effect before moving to animal or human studies; like a prototype in a workshop, positive in vitro results can lower scientific risk and influence funding, timelines, and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Placentia, California--(Newsfile Corp. - December 9, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25 sales of $878,937, up 8.3% over FY '24. Net income of $121,980 advanced 14.3% for the same period.

CEO and Chairman, W. Richard Ulmer, offered his view of IVRO's progress: "In this past year, Regulatory Agencies around the world announced they have already, or will soon, cease funding for animal testing; some have stopped now. Further, some RA's state OECD validated NON-animal test results could be accepted immediately. IVRO offers such test methods & serves large industries such as cosmetics, chemical companies, and varieties of adhesives manufacturers, globally. Our now 40-year-old vision for industry movement from animal databased safety testing to in vitro testing appears on its way to reality."

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology driven provider of non-animal testing methods. The Company's testing technologies are designed to produce Regulatory Agencies' approved data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update such statements.

Company Contact:

W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277330

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were IVRO's FY 2025 sales and net income reported on December 9, 2025?

IVRO reported FY 2025 sales of $878,937 and net income of $121,980.

How much did IVRO's revenue change year‑over‑year in FY 2025?

Revenue increased by 8.3% compared with FY 2024.

What did IVRO say about regulatory agency decisions and animal testing in December 2025?

The company said some Regulatory Agencies have already or will soon cease funding animal testing and that some agencies indicated OECD‑validated non‑animal tests could be accepted immediately.

Which markets does IVRO serve with its in vitro test methods (OTCQB: IVRO)?

IVRO serves large industries including cosmetics, chemical companies, and adhesives manufacturers globally.

Does IVRO's FY 2025 performance indicate profitability improvement?

Yes; reported net income rose 14.3% year‑over‑year for FY 2025.